Daytryp Health, an up-and-coming psychedelic wellness center, announced today the opening of their first location in Phoenix, AZ. It is one of many locations that Daytryp is planning to open in 2023 and beyond. Located in the Arcadia neighborhood, the Phoenix location is the first Daytryp Health center to open this year, and will be followed by locations in Mesa, AZ and Bend, OR.
PHOENIX, Jan. 9, 2023 /PRNewswire-PRWeb/ -- Daytryp Health, an up-and-coming psychedelic wellness center, announced today the opening of their first location in Phoenix, AZ. It is one of many locations that Daytryp is planning to open in 2023 and beyond. Located in the Arcadia neighborhood, the Phoenix location is the first Daytryp Health center to open this year, and will be followed by locations in Mesa, AZ and Bend, OR.
Daytryp Health centers provide medically supervised ketamine therapy programs combined with psychotherapy in a tranquil, elegant atmosphere. Ketamine is a legal psychedelic compound that has been proven to help those suffering from treatment-resistant depression, anxiety, post traumatic stress disorder (PTSD), chronic pain, migraines, eating disorders, suicidal ideation, and substance and alcohol use disorders. Ketamine induces neuroplasticity, which is the brain's ability to change – to rewire, relearn and strengthen important connections. Neuroplasticity occurs after every ketamine treatment and can last for many days, providing the opportunity to quite literally "change people's minds," as well as their lives.
With the opening of the Phoenix office, Daytryp intends to establish itself as a pillar in the community, providing education on the efficacy and safety of psychedelic therapies on physical, emotional, and mental health. Unlike the majority of existing ketamine clinics, Daytryp applies a holistic approach to wellness with an emphasis on the integration process. The integration process refers to a number of ways in which Daytryp practitioners and "trip sitters" assist clients in processing and incorporating the insights gained from their ketamine treatment. Daytryp will also be participating in clinical trials of additional psychedelic treatments including psilocybin therapy and MDMA therapy.
Chris Cohn, founder and CEO of Daytryp Health stated, "We are very excited to announce Daytryp Health to our community and expand our reach in offering a groundbreaking, proven, and impactful mental health treatment via Ketamine Assisted Psychotherapy. We will emphasize the integration aspect of these therapies, therefore focusing on sustained relief from mental and spiritual health ailments. Our extensive research and clinical experience will provide those suffering from mental, physical, and spiritual ailments with novel and effective treatment pathways. Additionally, Daytryp will provide a vital role in educating providers and consumers about the therapeutic potential of safely utilizing psychedelic compounds in response to the ongoing mental health epidemic."
Chris Cohn spent the prior 15 years as Founder and CEO of a large drug and alcohol rehab program in Scottsdale, AZ. "After exiting the inpatient drug and alcohol rehab space after 15 years, I cosmically stumbled upon the world of psychedelic medicines for my own mental and spiritual healing. I knew in my heart this was the direction I wanted to go, particularly after all the clinical trials proved these psychedelic medicines to be so effective in healing many mental health ailments including substance abuse addiction, which I'm still very passionate about," said Cohn.
About Daytryp Health
Envisioned by leading mental health and psychedelic healthcare professionals, Daytryp Health is a privately owned family of psychedelic wellness centers in Arizona and Oregon, providing personalized treatment to help individuals and their loved ones break free from the cycle of chronic mental health and pain conditions.
For more information, please visit https://www.daytryp.com or call 1-833-DAYTRYP
Chris Cohn, Daytryp Health, 1 6028337714, firstname.lastname@example.org
SOURCE Daytryp Health
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.